Trial Profile
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLUOXETINE-REFERENCED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE (DVS SR) IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2019
Price :
$35
*
At a glance
- Drugs Desvenlafaxine (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 11 Jun 2015 Top line results published in the Media Release.
- 20 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Feb 2015 Planned number of patients changed from 390 to 333 as reported by ClinicalTrials.gov record.